References
Vondeling GT, Cao Q, Postma MJ, Rozenbaum MH. The impact of patent expiry on drug prices: a systematic literature review. Appl Health Econ Health Policy. 2018;16(5):653–60. https://doi.org/10.1007/s40258-018-0406-6.
Chaves GC, Oliveira MA, Hasenclever L, de Melo LM. Evolution of the international intellectual property rights system: patent protection for the pharmaceutical industry and access to medicines. Cad Saude Publica. 2007;23(2):257–67. https://doi.org/10.1590/S0102-311X2007000200002.
World Health Organization. Medicine availability of selected generic medicines. 2015. http://www.who.int/gho/mdg/medicines/availability/en/.
Diependaele L, Cockbain J, Sterckx S. Raising the barriers to access to medicines in the developing world—the relentless push for data exclusivity. Dev World Bioeth. 2017;17(1):11–21. https://doi.org/10.1111/dewb.12105.
Hug SE, Brändle MP. The coverage of Microsoft Academic: analyzing the publication output of a university. Scientometrics. 2017;113(3):1551–71. https://doi.org/10.1007/s11192-017-2535-3.
Thelwall M. Microsoft Academic: a multidisciplinary comparison of citation counts with Scopus and Mendeley for 29 journals. J Informetr. 2017;11(4):1201–12. https://doi.org/10.1016/j.joi.2017.10.006.
Haunschild R, Hug SE, Brändle MP, Bornmann L. The number of linked references of publications in Microsoft Academic in comparison with the web of science. Scientometrics. 2018;114(1):367–70. https://doi.org/10.1007/s11192-017-2567-8.
Punjabi SS, Johnsrud MT, Conner C. Economic impact of Prozac® patent expiration and the 180-day generic fluoxetine exclusivity in a publicly-financed prescription program. Val Health. 2003;6(3):192. https://doi.org/10.1016/S1098-3015(10)63837-5.
Keele MG, Butkow N, Venter D. Beyond patent expiry: development of a model for pricing generic drugs in South Africa. Val Health. 2013;16(7):A466. https://doi.org/10.1016/j.val.2013.08.828.
Riku J. Current situation for generic drugs in Japan. J Generic Medicines. 2005;2(3):219–31. https://doi.org/10.1057/palgrave.jgm.4940073.
Oh KY, Kim B, Kim T. Estimating market share function of generic drugs after patent expiration in Korea. Kor J Health Econ Policy. 2007;13(1):117–38.
Adriaen M, De Witte K, Simoens S. Pricing strategies of originator and generic medicines following patent expiry in Belgium. J Generic Med. 2008;5(3):175–87. https://doi.org/10.1057/jgm.2008.8.
Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol. 2009;62(10):1006–12. https://doi.org/10.1016/j.jclinepi.2009.06.005.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of Interest
We, Carlos Vílchez-Román, Sol Sanguinetti and Edward Mezones-Holguín declare no potential conflict of interest with respect to the research, authorship, and/or publication of this article. For this article, Carlos Vílchez-Román received funding from CENTRUM Católica Graduate Business School (CCGBS), and Sol Sanguinetti received funding from Universidad de Lima (ULima).
Rights and permissions
About this article
Cite this article
Vílchez-Román, C., Sanguinetti, S. & Mezones-Holguín, E. Comment on: “The Impact of Patent Expiry on Drug Prices: A Systematic Literature Review”. Appl Health Econ Health Policy 17, 255–256 (2019). https://doi.org/10.1007/s40258-018-0441-3
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40258-018-0441-3